ReviewNeonatal hemolysis and risk of bilirubin-induced neurologic dysfunction☆
Introduction
Neonatal jaundice is a benign condition occurring in 65–85% of all healthy term and late preterm infants. It is a result of a combination of naturally occurring factors in an infant's first week of life [1]. First, newborn infants have an increased red blood cell (RBC) turnover rate, which is up to two to three times that of a normal adult [2], [3]. Second, newborns have an impaired hepatic ability in the uptake and conjugation of bilirubin. This transitional imbalance of production and elimination is normal, but can be upset in several conditions, which are often associated with increased bilirubin production, such as prematurity, bruising (e.g., cephalhematoma), infants of diabetic mothers (IDM), ethnicity, cholestasis, and hemolysis. All these may further increase an infant's bilirubin load to cause severe unconjugated hyperbilirubinemia, especially in those infants with perinatal sepsis in countries with high neonatal mortality rates and among those with genetic predispositions where the rate of sepsis has been more efficiently managed [4]. Recent epidemiologic data show that there is an increased risk for bilirubin-induced neurotoxicity in infants with hemolytic disease regardless of its etiology [5]. Therefore, if these at-risk infants are unidentified or left untreated, bilirubin-induced neurological dysfunction (BIND) may develop and lead to long-term neurologic sequelae, and even kernicterus [4], [6], [7]. Therefore, developing novel technologies that can identify these at-risk infants may play a key role in reducing the incidence of BIND.
Section snippets
Causes of hemolysis
The American Academy of Pediatrics (AAP) in its 2004 guideline considers hemolysis as a major risk factor in the development of severe hyperbilirubinemia [8]. In fact, the guideline recommends administering phototherapy or performing exchange transfusions in neonates with hemolytic conditions at lower total serum/plasma bilirubin (TB) levels compared to those that are non-hemolysing, healthy newborns. Hemolysis in newborn infants can originate from a number of different conditions, which are
Genetic predispositions
Superimposed on this physiology is an infant's genetic predisposition, which can further impact rates of bilirubin production and elimination. Individuals can possess genetic variants that can affect bilirubin production or its elimination alone; or in some combination, thereby affecting both bilirubin production and elimination.
Assessment of hemolysis
Regrettably, there are no clinical tests or point-of-care devices currently available that can reliably detect ongoing hemolysis. Existing technologies can identify only those infants at high risk [36], [37]. These include blood bank screening of cord blood for ABO incompatibilities and blood collection, which are invasive, used for determinations of Rh type, TB, and direct antiglobulin test (DAT) or Coombs positivity.
Risk of BIND associated with neonates with hemolytic disease
It is now well recognized that an increased bilirubin production rate is a major cause of severe hyperbilirubinemia. Because all neonates have a transiently impaired elimination of bilirubin, disorders in hepatic uptake, conjugation, and enterohepatic circulation can exacerbate the transitional neonatal jaundice and lead to severe hyperbilirubinemia. Infants are at more risk for injury because of their absolute bilirubin level, binding capacity, and clinical circumstances that might alter their
Summary
Although severe hyperbilirubinemia can be best understood with regards to complications related to the uptake and conjugation of bilirubin, the hyperbilirubinemia requiring treatment in newborn infants most frequently observed by the pediatrician is associated with increased bilirubin production, and most likely due to hemolysis, which is often further exacerbated by environmental or genetic factors. Thus, early identification of these infants combined with a therapeutic approach aimed at
Conflict of interest statement
None declared.
Acknowledgments
We would like to thank the Mary L. Johnson Research Fund, Christopher Hess Research Fund, and the HML for their generous support of our work throughout the years.
References (74)
- et al.
Bilirubin production and the risk of bilirubin neurotoxicity
Semin Perinatol
(2011) - et al.
The clinical syndrome of bilirubin-induced neurologic dysfunction
Semin Perinatol
(2011) - et al.
Erythrocyte disorders in the perinatal period
Semin Perinatol
(2007) - et al.
Cytokine production, glutamate release and cell death in rat cultured astrocytes treated with unconjugated bilirubin and LPS
J Neuroimmunol
(2004) - et al.
Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm
Thromb Res
(2002) - et al.
The effect of a promoter polymorphism in the heme oxygenase-1 gene on the risk of ischaemic cerebrovascular events: the influence of other vascular risk factors
Thromb Res
(2004) - et al.
Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema
Am J Hum Genet
(2000) - et al.
Increased risk of gastric cancer in Japanese subjects is associated with microsatellite polymorphisms in the heme oxygenase-1 and the inducible nitric oxide synthase gene promoters
Cancer Lett
(2008) - et al.
Influence of polymorphism within the heme oxygenase-I promoter on overall survival and transplantation-related mortality after allogeneic stem cell transplantation
Biol Blood Marrow Transplant
(2008) - et al.
Deficiency of heme oxygenase-1 impairs renal hemodynamics and exaggerates systemic inflammatory responses to renal ischemia
Kidney Inter
(2007)
The role of heme oxygenase-1 promoter polymorphisms in human disease
Free Rad Biol Med
Glucose-6-phosphate dehydrogenase deficiency: a hidden risk for kernicterus
Semin Perinatol
G6PD deficiency
Blood
Conjugated bilirubin in neonates with glucose-6-phosphate dehydrogenase deficiency
J Pediatr
Glucose-6-phosphate dehydrogenase deficiency, the UDP-glucuronosyl transferase 1A1 gene, and neonatal hyperbilirubinemia
Gastroenterology
Gilbert’s syndrome and hyperbilirubinaemia in ABO-incompatible neonates
Lancet
Prevalence and lack of clinical significance of blood group incompatibility in mothers with blood type A or B
J Pediatr
Metabolism of carbon monoxide by the colonic flora of humans
Gastroenterology
Microsomal heme oxygenase. Characterization of the enzyme
J Biol Chem
Carbon monoxide and carboxyhemoglobin
Adv Pediatr
Role of hemolysis in neonatal jaundice associated with glucose-6 phosphate dehydrogenase deficiency
J Pediatr
Unbound bilirubin associated with kernicterus: a historical approach
J Pediatr
Cytotoxicity of bilirubin for human fibroblasts and rat astrocytes in culture. Effect of the ratio of bilirubin to serum albumin
Clin Chim Acta
Does hyperbilirubinemia damage the brain of healthy full-term infants?
Clin Perinatol
Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns
Pediatrics
Bilirubin production in healthy term infants as measured by carbon monoxide in breath
Clin Chem
Carbon monoxide excretion as an index of bilirubin production in rhesus monkeys
J Med Primatol
Synopsis report from the pilot USA Kernicterus Registry
J Perinatol
Bilirubin neurotoxicity in preterm infants: risk and prevention
J Clin Neonatol
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation
Pediatrics
Severe neonatal jaundice associated with glucose-6-phosphate dehydrogenase deficiency: pathogenesis and global epidemiology
Acta Paediatr Suppl
Response to commentaries re: evaluation and treatment of jaundice in the term newborn: a kinder, gentler approach
Pediatrics
Kernicterus in otherwise healthy, breast-fed term newborns
Pediatrics
Heme degradation and human disease: diversity is the soul of life
Antioxid Redox Signal
The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase
Proc Natl Acad Sci USA
A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease
Thromb Haemost
Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer
Cancer Epidemiol Biomark Prev
Cited by (18)
Mechanisms of redox interactions of bilirubin with copper and the effects of penicillamine
2017, Chemico-Biological InteractionsCitation Excerpt :Hyperbilirubinemia, the accumulation of bilirubin (BR) in the plasma and tissues, is often observed in newborns. It develops due to high turnover of erythrocytes and hepatic immaturity, but also in relation to some pathological conditions, such as hemolytic diseases and sepsis [1,2]. BR levels exceeding physiological concentrations more than 20-fold, labeled as severe hyperbilirubinemia, may result in neural damage, promoted hemolysis and general cellular injury, and increased risk of sepsis [3–5].
Ferroptosis contributes to hemolytic hyperbilirubinemia-induced brain damage in vivo and in vitro
2023, Molecular Medicine ReportsHemolytic causes of neonatal jaundice: Diagnosis and treatment
2021, Pediatric MedicineThe biology of bilirubin production: Detection and inhibition
2021, Pediatric Medicine
- ☆
Portions of this review were presented at the Bilirubin Club held at the Pediatric Academic Societies 2013 Annual Meeting in Washington, DC, on May 4, 2013.